{
}
UBS has maintained a Buy rating for Sarepta Therapeutics with a price target of $188, despite a recent patient death linked to its gene therapy Elevidys, which has caused the stock to drop over 26%. Analyst Eliana Merle views the market reaction as exaggerated and emphasizes the ongoing demand for Elevidys, the only approved treatment for Duchenne muscular dystrophy. While some analysts express caution regarding safety and sales forecasts, others remain optimistic about the drug's potential and future revenue growth.
Sarepta Therapeutics' shares saw volatility following a patient's death linked to its gene therapy, Elevidys, yet UBS analyst Eliana Merle maintained a Buy rating with a target of USD 188, viewing the market's reaction as an overreaction. Despite the incident, demand for Elevidys remains strong, and revenue growth is robust at 53% year-over-year. Analysts' responses vary, with some expressing caution while others uphold positive outlooks for the company's future performance.
UBS has reaffirmed a Buy rating on Inspire Medical Systems (NYSE: INSP) with a price target of $265, reflecting strong Wall Street sentiment amid the company's robust financial health and growth potential. Despite an ongoing Department of Justice investigation, analysts remain optimistic, citing a significant earnings beat and positive guidance for 2025, with expected sales of $940-955 million and EPS between $2.10 and $2.20. Other firms, including RBC Capital Markets and Piper Sandler, also maintain favorable ratings, underscoring the company's operational excellence and resilience.
Guardant Health, a precision oncology company, has seen significant activity from institutional investors, who now own 92.60% of its stock. Recent earnings revealed a revenue increase of 33.9% year-over-year, despite a loss of $0.88 per share, missing estimates. Analysts maintain a "Buy" rating, with a consensus price target of $41.81, while insiders have recently sold shares, indicating mixed signals about the company's future.
Barclays has reaffirmed its Overweight rating on Replimune Group, maintaining a $17 price target, indicating significant upside potential from its current price of $11.66. This optimism is driven by the FDA's acceptance of the Biologics License Application for RP1, a treatment for advanced melanoma, which is under priority review with no identified issues. Analysts from various firms have also expressed confidence in Replimune, with price targets ranging from $14 to $31, highlighting the company's strong liquidity and innovative pipeline.
Halozyme Therapeutics has made an unsolicited bid to acquire Evotec for 11 euros per share, totaling around 2 billion euros, aiming to enhance its strategic position in the drug industry. Bluebird bio has recorded its first revenue from its gene therapy Lyfgenia for sickle cell disease, while BeiGene has rebranded as BeOne Medicines to emphasize its oncology focus and distance itself from its Chinese roots. Adaptimmune plans to lay off a third of its workforce to save $300 million and focus on its cell therapy Tecelra, while Abeona Therapeutics awaits a decision from the FDA on its gene therapy pz-cel for a rare skin condition by April 2025.
Leerink Partners has expanded its team by hiring Jason Truman and Grant Curry as senior managing directors from Guggenheim Securities and Gordon Dyal & Co. This move is part of the firm's ongoing recruitment efforts in the health-care advisory sector.
Neurogene has secured $200 million through a PIPE financing deal, extending its cash reserves into late 2027. The funds will support the development of NGN-401 for Rett syndrome and advance its pipeline, which includes a candidate for Batten disease. Following the announcement, shares surged 40%, bolstering expectations for positive interim results expected next week.
Leerink Partners LLC
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
analysts divided on sarepta therapeutics after patient death linked to elevidys
United States Dollar
JPMorgan U.S. Research Enhanced Large Cap ETF
Leerink Partners LLC
Arrowhead Pharmaceuticals, Inc.
REGENXBIO Inc.
Cantor Fitzgerald Equity Opp A
H.C. Wainwright & Co. LLC
Sarepta Therapeutics, Inc.
USA
Eliana Merle
Show more
16:08 19.03.2025
analysts divided on sarepta therapeutics after patient death linked to elevidys
United States Dollar
JPMorgan U.S. Research Enhanced Large Cap ETF
Leerink Partners LLC
Arrowhead Pharmaceuticals, Inc.
REGENXBIO Inc.
Cantor Fitzgerald Equity Opp A
H.C. Wainwright & Co. LLC
Sarepta Therapeutics, Inc.
USA
Eliana Merle
Show more
16:08 19.03.2025
ubs maintains buy rating on inspire medical with target price of 265
Morgan Stanley
Inspire Medical Systems, Inc.
Truist Securities Inc.
Leerink Partners LLC
Piper Sandler Cos
USA
Show more
17:25 11.02.2025
guardant health sees increased institutional investment and analyst ratings
JPMorgan Chase & Co.
Leerink Partners LLC
Wexford Capital LP
Mirae Asset Global Investments Co. Ltd. - Mirae Asset Tiger Global Artificial Intelligence & Robotic
Guggenheim High Yield P
Sanford C. Bernstein Fund, Inc. - Tax-Aware Overlay B Portfolio
The Goldman Sachs Group, Inc.
Guardant Health, Inc.
Barclays PLC
USA
Musa Tariq
Meghan Joyce
Show more
14:42 23.01.2025
barclays maintains positive outlook on replimune with 17 dollar price target
20:53 21.01.2025
halozyme bids for evotec bluebird bio records first revenue beiGene rebrands
Euro
Leerink Partners LLC
Abeona Therapeutics Inc.
Evotec SE
Adaptimmune
Halozyme Therapeutics, Inc.
BeOne Medicines
bluebird bio, Inc.
USA
Grant Curry
Ned Pagliarulo
Ben Fidler
Jason Truman
Show more
01:00 15.11.2024
Leerink Partners expands team with hires from Guggenheim and Gordon Dyal
18:42 13.11.2024
neurogene raises 200 million to advance gene therapy for rett syndrome
Samsara Biocapital LP
Purespring Therapeutics
Ecor1 Capital LLC
AvenCell Therapeutics
Leerink Partners LLC
Arsenal Biosciences
RTW Investments LP
Neurogene Inc.
Mani Foroohar
Joe Biden
Show more
18:22 04.11.2024
Trending
Subcategory
Corporate News
Industry Trends
Startups & Entrepreneurship
Retail and Consumer Goods
Global Trade Developments
Supply Chain Management
Stock Market Updates
Government Economic Policies
Industry Mergers & Acquisitions
Private Equity Deals
Fintech Startups
Energy Sector Developments
AI Applications
Funding Rounds & Investments
Venture Capital Investments
AI Innovations
Emerging Startups
CEO Changes
Inflation and Monetary Impact
IPOs & SPACs
Countries:
Companies:
Apple Inc.
Google Inc.
Tesmec S.p.A.
Amazon.com, Inc.
Microsoft Corporation
Mastercard Inc
NVIDIA Corp
Tesla, Inc.
OpenAI ERC USD
The Goldman Sachs Group, Inc.
Visa Inc.
SWIGGY LIMITED
GLOE Inc.
Ripple USD USD
NAURA Technology Group Co., Ltd.
OLA ELECTRIC MOBILITY LTD
Microsoft Corp
Micron Technology, Inc.
Foxconn Technology Co., Ltd.
SAP SE
Currencies:
United States Dollar
Indian Rupee
Chinese Yuan
Euro
United Arab Emirates Dirham
Japanese Yen
British Pound Sterling
Saudi Riyal
New Zealand Dollar
Qatari Riyal
Thai Baht
Vietnamese Đồng
Canadian Dollar
Indonesian Rupiah
South Korean Won
Malaysian Ringgit
Brazilian Real
Swiss Franc
Bangladeshi Taka
Kuwaiti Dinar
People: